Author Question: A patient says, I have such bad seasonal allergies. Is there anything I can take to keep them from ... (Read 66 times)

sam.t96 · **on:** Jul 23, 2018

A patient says, I have such bad seasonal allergies. Is there anything I can take to keep them from happening? What information should the nurse provide?

1. Some antihistamines can help prevent onset of allergies.
2. Some patients find that intranasal corticosteroids help prevent their allergies.
3. Drugs that are mast cell stabilizers may help you avoid your seasonal allergies.
4. Oral decongestants can help you prevent allergies.
5. Nasal decongestants are very good at preventing allergic response.

Question 2

First-pass effect can result in a large fraction of an administered drug being metabolically deactivated. Which client factors will decrease the magnitude of the first-pass effect?(Select all that apply.)

1. Elderly client
2. Hepatic disease
3. Gallbladder disease
4. Renal disease
5. Parenteral medication administration

millet · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

1,2,3
Rationale 1: Antihistamines are preventers of allergies.
Rationale 2: Intranasal corticosteroids are preventers of allergies.
Rationale 3: Mast cell stabilizers are preventers of allergies.
Rationale 4: Oral decongestants are relievers of allergic symptoms.
Rationale 5: Nasal decongestants are relievers of allergic symptoms.

Global Rationale: Antihistamines, intranasal corticosteroids, and mast cell stabilizers are preventers of allergies. Oral and nasal antihistamines are relievers of allergic symptoms.

Answer to Question 2

1, 2

Rationale 1: Elderly clients have reduced enzyme activity; thus, first-pass effect is reduced in this population.
Rationale 2: Liver enzymes are the major metabolic pathway for deactivation of most drugs, and clients with liver disease have decreased amounts of liver enzymes. First-pass effect will be diminished in these clients.
Rationale 3: The gallbladder is not involved in first-pass effect.
Rationale 4: The kidneys are not involved in first-pass effect.
Rationale 5: Medications given parenterally are not affected by the first-pass effect.

Global Rationale: Elderly clients have reduced enzyme activity; thus, first-pass effect is reduced in this population. Liver enzymes are the major metabolic pathway for deactivation of most drugs, and clients with liver disease have decreased amounts of liver enzymes. First-pass effect will be diminished in these clients. The gallbladder is not involved in first-pass effect. The kidneys are not involved in first-pass effect. Medications given parenterally are not affected by the first-pass effect.